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The increasing incidence of malignant diseases that often require gonadotoxic treatment and the
tendency to become parent later, results in an increased need for fertility preservation.
The following review summarizes different options for fertility preservation addressed to pre-
puberal girls and women at reproductive ages whose fertility has been compromised. They include
embryo, unfertilized oocytes and ovarian tissue cryopreservation.
The review also consider new improvements that are being studied for these procedures and recent
advances in this field which can open a door to novel treatments for human infertility and fertility
preservation.
1. Abstract 
Scientific literature search on PubMed based on specific words such as: fertility preservation, oocyte and
embryo cryopreservation and so on. The research has been focused on recent papers and reviews.
Assisted in a conference organized by Víctor Grífols and Lucas Foundation about the 30th anniversary of
the first child born in Spain after IVF.
2. Materials and Methods
4.Options to Preserve Female Fertility
•Female fertility is based on a pool of non-growing follicles in the ovary, some of which start growing every day.
This procedure becomes gonadotrophin dependent and ends with ovulation.
•Female fertility preservation has become an interesting matter for society in the last time. This interest has
grown due to the increasing rates of cancer in young population and the delay in childbearing for social
issues (following diagram). Cancer treatments (in pre-puberal and fertile women) cause follicle loss which implies
an alteration of reproductive potential.
3. Introduction 
• Procedure: remove ovarian grafts (fig. 3) and freeze them. When they are
frozen, tissues can be stored in order to use them in the future. Lately,
ovarian strips can be thawed and grafted to orthotopic or heterotopic site
in the body. Strips have to restore ovarian endocrine function permeating
oocyte maturation. Pregnancies after transplantation can occur by natural
conception or after IVF techniques.
• Indications: addressed to pre-puberal girls who have to be subjected in
invasive treatments.
• Advantages:1) No ovarian stimulation is need, 2) All ages, 3) no male is
need.
• Disadvantages: 1) requires surgery, 2) risk of reimplant malignant cells.
• Procedure: Used for embryo cryopreservation. Slow freezing protocols
consist in cooling the samples by cooling rates (fig. 4). In order to prevent
intracellular ice formation and toxic concentrations of solutes the freezing solution
must be supplemented with cryoprotective additives (CPA).Once embryos are in
LN2 they can be stored for a long time.
• Indications: addressed to women in reproductive age who want to delay
motherhood or women who have to be submitted on invasive treatment.
• Advantages:1) No surgical procedure, 2) No risk of reimplant malignant cells,
3) long time storage.
• Disadvantages: 1) Ovarian stimulation is need, 2) Not indicated for pre-puberal
girls, 3) male is need. 4) embryo ethical concerns, 5) Requires IVF.
• Procedure: used for both embryo and oocyte cryopreservation.
Consist in super rapid cooling procedure (Fig. 5) achieved by putting the
samples in direct contact with LN2. The aim of vitrification is to prevent ice
formation and too fast dehydration oocyte/embryo, that’s the reason why
concentrations of CPA are extremely high.
• Indications: addressed to women in reproductive age who want to delay
motherhood or women who have to be submitted on invasive treatment.
• Advantages:1) No surgical procedure, 2) No risk of reimplant malignant
cells, 3) long time storage, 4) oocyteless ethical concerns.
• Disadvantages: 1) Ovarian stimulation is need, 2) Not indicated for pre-
puberal girls, 3) male is need. 4) embryoethical concerns, 5) Requires
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Fig 1: Illustration of the decline in primordial follicle number due to 
Cisplatin, a chemotherapeutic agent. A) control cultured mouse 
ovary, arrows indicate primordial follicles, B) mouse ovary after 
Cisplatin treatment [1].
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5. Future Goals
The future of female fertility preservation comes to us by two different ways:
1. Groups who want to improve and optimize procedures and techniques used nowadays in clinic practices: ovarian tissue,
embryo and oocyte cryopreservation.
2. Researches interested in looking for new strategies far from cryopreservation. Stem cells-based strategies (table) for ovarian
regeneration and oocyte production has been proposed as future clinical therapies for female infertility.
Table: Characteristics of stem cells used in stem cell-based therapy research of infertility.
6. Conclusions
The need for female fertility preservation is emerging because the incidence of cancer in young population
is increasing and its treatment usually leads to infertility. Fertility preservation is also needed because many
womenprefer to postpone childbearing.
Nowadays there are some options available in order to preserve female fertility, most common are: ovarian
tissue, oocyte and embryo cryopreservation. These techniques consist in freezing the samples following
different protocols according to their characteristics and storing them in LN2 for future applications.
Not all procedures can be used for all patients: while ovarian tissue cryopreservation is more suitable for
pre-puberal girls, oocyte and embryo cryopreservation is the main election for women at reproductive ages.
Protocols about samples cryopreservation have been designed to prevent as much as possible cell alterations
and death. Survival rates for slow frozen oocytes are much lower than vitrified ones, that’s the reason why
slow freezing for oocytes has not been used anymore in clinics.
Future goals on female fertility preservation are the improvements and optimization of current procedures.
There are some researchers looking for new strategies, they believe that an ideal fertility preservation
approach would prevent delays in commencing live-saving treatment and avoid transplanting malignant cells
back . Stem cells strategies (in particular OSCs) may offer one route to achieve this goal.
Fig 3: Large ovarian cortical strips 
prepared for transplantation. They have 
been thawed after having been stored in 
low temperatures [3].
Fig 5: Typical vitrification cooling 
curve. Samples are introduced in LN2
without using cooling rates. The 
procedure is really fast [4].
Fig 4: Slow freezing cooling rates. Lowering 
temperature is made in different times At 7ºC 
ice seeding is induced. Then cooling 
procedure continues since LN2.
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